ICOS Agonist mAbs Demonstrate Single-agent Antitumor Activity in Mouse Tumor Models
tumor, breast cancer
TUMOR, BREAST CANCER
To evaluate the antitumor potential of ICOS agonism, we treated EMT6 (syngeneic breast cancer model) tumor-bearing mice with an anti-mouse ICOS mAb [an Fc variant of 7E.17G9 mouse (m)IgG1]. To better parallel the Fc-Fcγ receptor biology of feladilimab, 7E.17G9 was grafted on an Fc region with reduced potential for coengagement with activating FcγR (mIgG1). Effective tumor control was observed in mice administered with 7E.17G9 at a range of doses associated with clinically tolerable exposure (0.5, 5, and 10 mg/kg; ICOS agonist mAbs demonstrate single-agent antitumor activity. 